Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: Evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay

Cesare Astori, Maurizio Bonfichi, Guido Pagnucco, Paolo Bernasconi, Mario Lazzarino, Ester Orlandi, Carlo Bernasconi

Research output: Contribution to journalArticlepeer-review

Abstract

We describe a 28-year-old man with paroxysmal nocturnal haemoglobinuria (PNH) and a high transfusion requirement. Prior to and during therapy with recombinant human erythropoietin (rHuEpo), we evaluated the levels of 'decay- accelerating factor', CD55, and 'membrane-inhibitor-of-reactive-lysis', CD59, as markers of the disease, whilst CD58, a marker present on leucocytes, was utilized to monitor normal haemopoietic activity. The patient became transfusion independent 1 month after beginning rHuEpo and remains well. The analysis of cD55, CD59 and CD58 suggests that the efficacy of rHuEpo was due to a selective rHuEpo action on normal erythroid clones.

Original languageEnglish
Pages (from-to)586-588
Number of pages3
JournalBritish Journal of Haematology
Volume97
Issue number3
Publication statusPublished - 1997

Keywords

  • DAF-CD55
  • MIRL-CD59
  • paroxysmal nocturnal haemoglobinuria
  • recombinant human erythropoietin
  • treatment

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Treatment with recombinant human erythropoietin (rHuEpo) in a patient with paroxysmal nocturnal haemoglobinuria: Evaluation of membrane proteins CD55 and CD59 with cytofluorometric assay'. Together they form a unique fingerprint.

Cite this